This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Azoulay-Dupuis, E Articles by Pocidalo, J J Search for Related Content PubMed PubMed Citation Articles by Azoulay-Dupuis, E Articles by Pocidalo, J J

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1991 June; 35(6): 1024-1028

Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia.

Hôpital Claude Bernard, Institut National de la Santé et de la Recherche Médicale U.13, Paris, France.

ABSTRACT

Azithromycin is a new acid-stable 15-membered-ring macrolide that exhibits an extended half-life and excellent tissue distribution, including distribution in the lung. We compared its in vivo activity with that of erythromycin using two models of Streptococcus pneumoniae pneumonia, namely, a model of acute infection in Swiss mice and a model of subacute infection in C57BL/6j mice. Female mice were infected by oral delivery into the trachea of 10(5) CFU of a virulent serotype 3 strain of S. pneumoniae (P 4241). Prophylactic and therapeutic treatments were given orally (p.o.) or subcutaneously (s.c.) by various regimens. In the model of subacute infection, a single dose of azithromycin, 25 mg/kg, given p.o. 7 h before infection protected 92% of the mice, while erythromycin was completely ineffective. In the model of acute infection, a single dose of azithromycin, 50 mg/kg, given s.c. 24 h prior to challenge protected 80% of the mice, whereas only 35% of the mice survived with erythromycin, 50 mg/kg, 1 h before challenge. Therapy, which was studied exclusively in the model of subacute infection, was initiated 48 h postinfection. Two doses of 12.5 mg/kg given p.o. 12 h apart resulted in 80% survival of mice treated with azithromycin versus 7% survival of mice treated with erythromycin. Pulmonary clearance of bacteria was consistent with the survival rates. Two doses (25 mg/kg) of azithromycin given s.c. at 48 and 65 h after infection led to complete clearance of bacteria from the lungs and blood, whereas erythromycin-treated mice remained bacteremic. The pharmacokinetics of azithromycin account for its superior efficacy against S. pneumoniae pneumonia relative to the efficacy of erythromycin.

This article has been cited by other articles:

• Burkhardt, O., Majcher-Peszynska, J., Borner, K., Mundkowski, R., Drewelow, B., Derendorf, H., Welte, T. (2005). Penetration of Ertapenem Into Different Pulmonary Compartments of Patients Undergoing Lung Surgery. J Clin Pharmacol 45: 659-665 [Abstract] [Full Text]  
• Honeybourne, D., Banerjee, D., Andrews, J., Wise, R. (2001). Concentrations of gatifloxacin in plasma and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 48: 63-66 [Abstract] [Full Text]  
• Byl, B., Jacobs, F., Roucloux, I., de Franquen, P., Cappello, M., Thys, J.-P. (1999). Penetration of Meropenem in Lung, Bronchial Mucosa, and Pleural Tissues. Antimicrob. Agents Chemother. 43: 681-682 [Abstract] [Full Text]  
• Bergeron, Y., Ouellet, N., Deslauriers, A.-M., Simard, M., Olivier, M., Bergeron, M. G. (1998). Cytokine Kinetics and Other Host Factors in Response to Pneumococcal Pulmonary Infection in Mice. Infect. Immun. 66: 912-922 [Abstract] [Full Text]  
• den Hollander, J. G., Knudsen, J. D., Mouton, J. W., Fuursted, K., Frimodt-Møller, N., Verbrugh, H. A., Espersen, F. (1998). Comparison of Pharmacodynamics of Azithromycin and Erythromycin In Vitro and In Vivo. Antimicrob. Agents Chemother. 42: 377-382 [Abstract] [Full Text]